Covestor有限公司在生物技术公司Biogen Inc.的股份急剧增加了近282%。 Covestor Ltd. dramatically increased its stake in Biogen Inc., a biotech firm, by nearly 282%.

科韦斯托尔有限公司在Biogen公司(一家开发神经疾病治疗的生物技术公司)的股份大幅增长,在问题4中增加了282.4%,目前持有325股股份。 Covestor Ltd significantly increased its stake in Biogen Inc., a biotech firm developing treatments for neurological diseases, by 282.4% in Q4, now holding 325 shares. 生物基因的存货价值为50 000美元,商定价格目标为213.15美元,该年的EPS预测值为15.83美元。 Biogen's stock, valued at $50,000, has a consensus price target of $213.15 and an EPS forecast of 15.83 for the year. 分析师认为股票"持有". Analysts rate the stock as "Hold." 该公司的市场上限为174.6亿美元,P/E比率为10.66。 The company's market cap is $17.46 billion with a P/E ratio of 10.66. Kennedy Capital and Synovus Financial Corporation等其他机构也增加了其在Biogen的持有量。 Other institutions like Kennedy Capital and Synovus Financial Corp have also increased their holdings in Biogen.